Lunesta (Eszopiclone) in Adolescents Ages 12 to 17: Transitioning to Adult Care

Why Eszopiclone Use in Adolescents Requires Special Attention

Eszopiclone does not carry an FDA-approved indication for anyone under 18. A 2014 randomized controlled trial of eszopiclone in children and adolescents with ADHD-related insomnia (N=483, ages 6 to 17) found no significant improvement in sleep latency versus placebo, and the FDA subsequently declined to approve a pediatric label. Any adolescent receiving it today is, by definition, an off-label patient.

The Regulatory Gap

The FDA's 2014 Complete Response Letter for pediatric eszopiclone cited insufficient efficacy data and raised concerns about next-day sedation in developing brains. The Pediatric Research Equity Act requires manufacturers to study drugs in children when the adult condition also occurs in minors, but Sunovion's supplemental application did not meet the efficacy threshold. Prescribers who continue eszopiclone in a 17-year-old transitioning to 18 must document medical necessity and obtain renewed informed consent under adult standards.

Prevalence of Adolescent Insomnia

Chronic insomnia affects roughly 10 to 15% of adolescents in the United States, based on population-level data reviewed in a 2019 systematic review published in Sleep Medicine Reviews [1]. Comorbid psychiatric disorders, notably depression and anxiety, drive a large share of cases. Because insomnia in this age group is so often secondary, pharmacotherapy without concurrent behavioral treatment rarely resolves the underlying cause, a consideration that becomes more pressing when the patient crosses into adult care.

Why the Transition Moment Matters

At age 18, prescribing authority shifts, insurance panels change, and the legal framework for consent becomes the patient's own. A teen who has taken eszopiclone nightly for six months enters adulthood already at risk for physiologic dependence. Without a structured handoff plan, that patient may receive a new prescription from a primary care provider who is unaware of the prior duration of use, inadvertently extending a course that should have been reconsidered.

What Adult-Care Guidelines Actually Say About Eszopiclone

The American Academy of Sleep Medicine 2017 clinical practice guideline on chronic insomnia disorder in adults states: "We suggest that clinicians use eszopiclone as a treatment for sleep onset and sleep maintenance insomnia in adults (GRADE: weak recommendation, moderate-quality evidence)" [2]. That guideline applies from age 18 onward, which is precisely the threshold at which transitioning patients land.

GRADE Evidence and What It Means for New Adult Patients

A "weak recommendation, moderate-quality evidence" rating means the guideline committee was not confident that benefits clearly outweigh harms for all adults. For a newly minted 18-year-old with a history of nightly use, the benefit-to-risk calculus is different from a de novo adult patient. The receiving adult-care clinician should treat this patient more like someone with existing exposure than someone starting fresh.

Cognitive Behavioral Therapy for Insomnia as the Preferred First Step

AASM guidelines and a 2015 NIH Pathways to Prevention Workshop consensus both position Cognitive Behavioral Therapy for Insomnia (CBT-I) as the first-line treatment for chronic insomnia in adults, ahead of any pharmacologic agent [3]. A transitioning adolescent who has never completed a structured CBT-I course (typically 6 to 8 sessions) should be referred to one before the adult prescriber renews eszopiclone. Completion rates for digital CBT-I programs among young adults ages 18 to 25 run approximately 64 to 72%, based on a 2021 trial of Sleepio (N=1,711) published in JAMA Psychiatry [4].

Maximum Approved Adult Doses

Adult prescribing starts at 1 mg immediately before bed. The FDA label permits titration to 2 mg or 3 mg for sleep maintenance insomnia. Women and older adults metabolize eszopiclone more slowly; the FDA recommends a 1 mg starting dose and a 2 mg maximum for women specifically, following 2014 label updates that applied lessons learned from similar changes to zolpidem labels [5]. An 18-year-old female transitioning from an off-label adolescent course should be re-titrated under female-specific dosing guidance from day one of adult care.

Tapering Protocols Before or During the Transition

Abrupt discontinuation of eszopiclone after prolonged nightly use can produce rebound insomnia, anxiety, and, in rare cases, seizure. A structured taper is the standard approach.

Standard Taper Framework

A practical taper schedule for adolescents transitioning off eszopiclone follows a three-phase approach:

Phase 1 (Weeks 1 to 2): Reduce the nightly dose by 25%. If the patient is on 2 mg, move to 1.5 mg. If on 1 mg, move to 0.5 mg (tablet can be split; pharmacist should confirm stability of the split tablet).

Phase 2 (Weeks 3 to 4): Reduce by another 25% of the original dose. Target every-other-night dosing when possible.

Phase 3 (Weeks 5 to 6): Discontinue with close follow-up at 7 days and 30 days after the last dose to screen for rebound symptoms.

Patients on eszopiclone for fewer than four weeks can typically taper over 7 to 10 days. Patients with a documented history of benzodiazepine or alcohol use disorder should taper over at least 8 weeks, and a consultation with addiction medicine is appropriate.

Monitoring During Taper

Sleep diary tracking during the taper captures objective rebound data without requiring polysomnography. Free validated tools include the Consensus Sleep Diary, developed through an NIH-funded consensus process and available without cost [6]. The clinician should also re-administer the Insomnia Severity Index (ISI) at the start of the taper and at the end of Phase 3. An ISI score above 14 at the end of Phase 3 suggests clinically significant insomnia remains and warrants reassessment rather than immediate re-prescription.

When to Pause or Reverse the Taper

Signs that warrant slowing or pausing the taper include ISI scores rising above 21 (severe insomnia range), emergence of suicidal ideation, or withdrawal symptoms such as diaphoresis, tremor, or tachycardia. In those cases, return to the last well-tolerated dose and involve psychiatry before proceeding.

Safety Profile Relevant to the 12 to 17 Age Group

Eszopiclone's safety concerns in adolescents overlap with adult concerns but carry added weight because the prefrontal cortex continues developing until approximately age 25.

Next-Day Sedation and Driving Risk

The FDA added a driving warning to all eszopiclone labels in 2014, noting that blood concentrations sufficient to impair driving performance can persist 8 hours after a 3 mg dose in some individuals [5]. An adolescent who drives to school needs at least 8 hours between the last dose and getting behind the wheel. Clinicians should document this counseling in the chart.

Dependence and Abuse Potential

Eszopiclone is a Schedule IV substance. A 2022 Drug Abuse Warning Network (DAWN) analysis found sedative-hypnotic agents (including eszopiclone) accounted for approximately 13% of emergency department visits related to misuse in the 12 to 17 age bracket [7]. Screening for concurrent alcohol or cannabis use is standard of care before any renewal in this population.

Psychiatric Adverse Events

The prescribing information for Lunesta includes a boxed warning added in 2019 covering complex sleep behaviors including sleepwalking, sleep-driving, and other behaviors while not fully awake. These behaviors have led to serious injuries [8]. Adolescents with a personal or family history of parasomnias should not receive eszopiclone without a formal sleep study to rule out underlying sleep-disordered breathing or non-REM parasomnias first.

Drug Interactions Relevant in Adolescents

CYP3A4 inhibitors, including ketoconazole, clarithromycin, and certain HIV protease inhibitors, can raise eszopiclone plasma levels by up to 2.2-fold, per the FDA label [8]. Adolescents receiving these agents concurrently should have eszopiclone doses capped at 1 mg. CNS depressants, including opioids, first-generation antihistamines, and certain antiepileptics, compound sedation risk and require documented risk-benefit assessment.

Building the Transition Plan: A Clinical Checklist

A clean handoff from pediatric or adolescent care to adult care for a patient on eszopiclone requires more than a prescription transfer. The following domains need documented review.

Diagnostic Re-Evaluation

Chronic insomnia in adolescents is frequently a symptom, not a standalone diagnosis. Before continuing eszopiclone into adulthood, the adult-care provider should confirm:

• The primary insomnia diagnosis still holds (rule out obstructive sleep apnea with STOP-BANG screening)
• PHQ-9 and GAD-7 scores have been obtained in the past 90 days
• Substance use history has been updated (CRAFFT screen for adolescents, AUDIT/DAST for adults 18+)
• Sleep hygiene and circadian factors (delayed sleep phase, which affects roughly 15% of adolescents, per a 2019 review in JAMA Pediatrics) have been addressed [9]

Documentation Transfer Requirements

The adult prescriber needs, at minimum: the original indication, start date, all dose changes, any prior taper attempts, adverse event history, and results of any prior CBT-I or sleep study. A structured transition summary, rather than a generic consult note, improves medication safety at handoff. The Joint Commission's 2023 National Patient Safety Goals cite medication reconciliation at care transitions as a priority area, specifically noting controlled substances [10].

Informed Consent for Adult Continuation

At 18, the patient signs their own consent. The adult prescriber must review the FDA boxed warning on complex sleep behaviors, the dependence and withdrawal risk, the driving warning, and the absence of long-term safety data beyond 12 months of use. Documenting that this conversation occurred protects both the patient and the provider.

Setting a Re-Evaluation Date

No adult patient should receive an open-ended eszopiclone prescription. The AASM recommends periodic reassessment, at minimum every 3 months for patients on nightly use [2]. For a newly transitioned 18-year-old, a 30-day and 90-day follow-up schedule is more appropriate than quarterly-only.

Alternatives to Eszopiclone at Transition

If the transition evaluation reveals that eszopiclone is no longer the best option, several alternatives have adult approval and different risk profiles.

Non-Benzodiazepine Receptor Agonists

Zolpidem (Ambien), zaleplon (Sonata), and eszopiclone share a pharmacologic class. Switching between them is rarely a solution if dependence is the concern. Their benefit-to-risk profiles in young adults are similar.

Orexin Receptor Antagonists

Suvorexant (Belsomra) and lemborexant (Dayvigo) block orexin signaling and carry a lower dependence profile than z-drugs. A 2019 meta-analysis of suvorexant trials (N=1,855) found significant improvements in sleep onset and total sleep time versus placebo with no evidence of physiologic dependence at 12 months [11]. Both are FDA-approved for adults, and lemborexant specifically showed efficacy in a phase 3 trial (SUNRISE-1, N=291) with a low next-day impairment signal at the 5 mg dose [12].

Melatonin Receptor Agonists

Ramelteon (Rozerem) is not a controlled substance and carries no boxed warning for complex sleep behaviors. It is approved for sleep onset insomnia in adults. For a transitioning patient whose primary complaint is difficulty falling asleep rather than staying asleep, ramelteon 8 mg at bedtime is a reasonable de-escalation option.

Low-Dose Doxepin

The FDA approved doxepin 3 mg and 6 mg specifically for sleep maintenance insomnia in adults in 2010. Unlike tricyclic antidepressants at antidepressant doses, low-dose doxepin is a histamine H1 antagonist at these concentrations. A 2012 phase 3 trial (N=221) demonstrated significant improvement in wake time after sleep onset without next-day sedation at 3 mg [13].

What Patients and Families Should Know

Patients transitioning out of adolescent care should receive written information, not just verbal counseling. The following points cover the clinical essentials in plain language.

Eszopiclone was prescribed off-label. That means it was used outside its FDA-approved age range, which is adults only. The decision to continue it at 18 requires a fresh evaluation, not an automatic refill.

Sleep therapy works. CBT-I produces durable improvements in sleep that outlast medication effects. A 2015 meta-analysis covering 20 randomized trials (N=1,162) found CBT-I superior to pharmacotherapy on long-term follow-up measures [14].

Stopping suddenly is risky. Any patient who has used eszopiclone nightly for more than two weeks should not stop without a taper plan from their provider.

Driving rules apply. Eight hours minimum between last dose and driving. A 1 mg dose still produces measurable psychomotor impairment in some individuals at 5 hours post-ingestion, per FDA review data [5].

Coordinating Between Pediatric and Adult Providers

Effective transitions require active communication, not passive record transfer. The Society for Adolescent Health and Medicine and the American Academy of Pediatrics jointly recommend using a structured transition readiness assessment tool, such as the Got Transition Six Core Elements framework, for all adolescents with chronic conditions or ongoing medication use [15].

For a patient on a controlled substance, that framework should include:

• A warm handoff call or shared electronic message between the outgoing and incoming prescribers
• Confirmation that the adult pharmacy has received the transfer and that no coverage gap exists for the taper supply
• A scheduled check-in at 2 weeks post-transition to catch any prescribing or access issues early

The ISI score at the time of transition serves as a useful baseline for the adult provider. Scores of 0 to 7 indicate no clinically significant insomnia; 8 to 14 indicate subthreshold insomnia; 15 to 21 indicate moderate severity; 22 to 28 indicate severe. Adult prescribers who receive a transition patient with an ISI of 15 or higher should prioritize a formal sleep assessment within the first 60 days.